SCHEMBL2483775

SCHEMBL2483775

CC(=C(C)c1ccc(O)c(CN2CCCC2)c1)c1ccc(O)c(CN2CCCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.61
TSHR P16473 2/20 0.59
GFER P55789 1/20 0.59
CACNA1B Q00975 5/20 0.59
L3MBTL1 Q9Y468 1/20 0.49
BACE1 P56817 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MPO P05164 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13338340 1.00 ACHE (0.61) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL2485226 1.00 ACHE (0.61) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL2484395 0.98 TSHR (0.62) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL16495328 0.98 TSHR (0.62) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL13338348 0.98 TSHR (0.62) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL2486252 0.87 ACHE (0.51) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL2483662 0.87 ACHE (0.51) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL13339343 0.87 ACHE (0.51) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL334483 0.86 L3MBTL1 (0.67) ACHETSHRGFERCACNA1BL3MBTL1
SCHEMBL2487271 0.85 ACHE (0.52) ACHETSHRGFERCACNA1BL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301159-A1 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF SOUTH FLORIDA (US) 2011-12-08 US claimed
EP-2376425-A2 KINASE INHIBITOR COMPOUNDS University of Florida Research Foundation, Inc. (US) 2011-10-19 EP claimed
WO-2010068710-A2 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-06-17 WO claimed
US-20140248634-A1 VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2014-09-04 US disclosed
WO-2013019655-A2 VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2013-02-07 WO disclosed
US-20110301159-A1 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF SOUTH FLORIDA (US) 2011-12-08 US disclosed
EP-2376425-A2 KINASE INHIBITOR COMPOUNDS University of Florida Research Foundation, Inc. (US) 2011-10-19 EP disclosed
WO-2010068710-A2 KINASE INHIBITOR COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301159-A1 KINASE INHIBITOR COMPOUNDS JAK2, JAK1, JAK3 ACHE 4871/4885TSHR 2741/4885GFER 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.